question for amex, page-10

I feel strongly that BTA should take away the license that GSK has clearly breached through Glaxo simply not having any interest in supporting Relenza after the merger with Smith Kline Beecham several years ago. It was a corporate decision to can Relenza as GSK were and still are heavily involved in vaccines in that area.

They are now reacting to new circumstances but they still breached the original agreement and so if they (GSK) do not offer a significant increase in royalty in line with the Roche/Gilead agreement then BTA should take the license and give it to someone else. As a very long time shareholder in BTA I feel it is time to play hard ball. If the current Board capitulates by accepting a significantly reduced offer then a special shareholders meeting should be called (or extraordinary AGM) to address this issue directly by addressing the composition of the Board. It is time BTA received due recompense for initiating this technology now seen to be worth several $B pa.